Siemens Healthcare to distribute Calypso GPS System in Europe

Aug 19 2010

Calypso Medical Technologies, Inc., a developer of real-time localization technology used for the precise tracking of tumor targets, today announced that it has entered into a non-exclusive product distribution agreement with Siemens Healthcare for the sale of its Calypso^® System in Europe. Under terms of the agreement, Siemens retains non-exclusive rights to sell Calypso's real-time tracking technology to existing and prospective Siemens linear accelerator customers throughout Europe for a period of three years.

“This distribution agreement with Calypso Medical allows us to offer our customers a comprehensive, state-of-the-art cancer treatment solution”

"Our distribution agreement with Siemens Healthcare marks an important milestone in our international expansion," said Jed Palmacci, vice president of global sales for Calypso Medical. "This agreement extends the availability of our GPS for the Body^® technology into geographic areas with significant incidences of prostate cancer. We are pleased that our real-time tracking technology will now serve a new patient base."

Last year Calypso Medical entered into a Master Development Agreement (MDA) with Siemens Healthcare to jointly develop products integrating the Calypso System with the Siemens ARTISTE linear accelerator and other Siemens radiotherapy technologies.

"This distribution agreement with Calypso Medical allows us to offer our customers a comprehensive, state-of-the-art cancer treatment solution," said Holger Schmidt, chief executive officer of Oncology Care Systems for Siemens Healthcare. "We are pleased to represent Calypso's technology throughout the European market."

With recent clinical findings of improved outcomes, Calypso's GPS for the Body^® technology enables doctors to localize and track the tumor before and during each radiation treatment. When the tumor moves outside of the field of radiation, therapy can be stopped while the patient is re-positioned to ensure that the tumor, not surrounding healthy tissue, receives the radiation dose. In contrast to other tumor targeting solutions, the Calypso System provides continuous tumor position information, objectively and without ionizing radiation, thereby safeguarding the patient from an additional non-therapeutic radiation dose.